Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Gw Pharmaceuticals (GWPRF)

Gw Pharmaceuticals (GWPRF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Gw Pharmaceuticals

Description:

GW Pharmaceuticals PLC was incorporated on February 15, 2001 under the laws of England and Wales. It is engaged in the research, development and commercialization of cannabinoid prescription medicines to meet patient needs. Its reportable segments are Sativex Commercial, Sativex Research and Development, and Pipeline Research and Development. The Sativex Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The current focus for this segment is the Phase III clinical development programme of Sativex for use in treatment of cancer pain. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using the Group's proprietary cannabinoid technology platform and partnerships with international scientists. The company has operations in the United Kingdom, Europe, United States, Canada and Asia. Trademark Epidiolex is registered in the United Kingdom and approved for publication in the United States. The Company is subject to regulation by federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.

Key Statistics

Overview:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K

Growth:

1-Year Return 54.55%
3-Year Return 51.65%
5-Year Return 119.03%

Per-Share Information:

Latest Earnings Date N/A
Dividend Payout Ratio 0.00%

GWPRF Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 6.03
Book Value/Share N/A
Interest Coverage N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar